SREBF1 and metabolic dysfunction-associated steatotic liver disease: These results align with the findings of Xiaoyan Sheng et al., who showed that targeting the liver X receptor to suppress SREBP-1c transcriptional activity and its downstream lipogenic enzymes, as well as participating in immune regulation associated with hepatic steatosis, could significantly improve NAFLD (Sheng et al. 2011).